RhumbLine Advisers’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

RhumbLine Advisers’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,318	Closed	-$21.7K	–	4300
2023 Q4	$21.7K	Buy	1,318 +1,176	+828%	+$18.5K	﹤0.01%	3759
2023 Q3	$1.1K	Hold	142	–	–	﹤0.01%	4173
2023 Q2	$736	Buy	+142	New	+$724	﹤0.01%	4301

RhumbLine Advisers's ORTX Position: Q1 2024 in Review

RhumbLine Advisers sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2024, closing a stake of 1,318 shares — an estimated $21.7K sold.

RhumbLine Advisers first reported a position in ORTX in Q2 2023 and held it in 3 quarters. The position peaked at $21.7K in Q4 2023. 0 funds tracked by Wall St. Rank hold ORTX as of Q1 2024.

RhumbLine Advisers reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
RhumbLine Advisers sold 1,318 Orchard Therapeutics plc American Depositary Shares shares in Q1 2024, an estimated $21.7K.
RhumbLine Advisers first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2023 and held it in 3 quarters.
RhumbLine Advisers's Orchard Therapeutics plc American Depositary Shares position peaked at $21.7K in Q4 2023.
0 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2024.

Based on RhumbLine Advisers's 13F filing for Q1 2024, filed 9 May 2024.